Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing
There are presently no reliable ways to quantify human pancreatic beta cell mass (BCM) in vivo, which prevents an accurate understanding of the progressive beta cell loss in diabetes or following islet transplantation. Furthermore, the lack of beta cell imaging hampers the evaluation of the impact o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/19/7274 |
| _version_ | 1797551993939558400 |
|---|---|
| author | Stephane Demine Michael L. Schulte Paul R. Territo Decio L. Eizirik |
| author_facet | Stephane Demine Michael L. Schulte Paul R. Territo Decio L. Eizirik |
| author_sort | Stephane Demine |
| collection | DOAJ |
| description | There are presently no reliable ways to quantify human pancreatic beta cell mass (BCM) in vivo, which prevents an accurate understanding of the progressive beta cell loss in diabetes or following islet transplantation. Furthermore, the lack of beta cell imaging hampers the evaluation of the impact of new drugs aiming to prevent beta cell loss or to restore BCM in diabetes. We presently discuss the potential value of BCM determination as a cornerstone for individualized therapies in diabetes, describe the presently available probes for human BCM evaluation, and discuss our approach for the discovery of novel beta cell biomarkers, based on the determination of specific splice variants present in human beta cells. This has already led to the identification of DPP6 and FXYD2γa as two promising targets for human BCM imaging, and is followed by a discussion of potential safety issues, the role for radiochemistry in the improvement of BCM imaging, and concludes with an overview of the different steps from pre-clinical validation to a first-in-man trial for novel tracers. |
| first_indexed | 2024-03-10T15:53:45Z |
| format | Article |
| id | doaj.art-3d5b350293834f4998cc635f9decf512 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T15:53:45Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-3d5b350293834f4998cc635f9decf5122023-11-20T15:49:04ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-10-012119727410.3390/ijms21197274Beta Cell Imaging—From Pre-Clinical Validation to First in Man TestingStephane Demine0Michael L. Schulte1Paul R. Territo2Decio L. Eizirik3Indiana Biosciences Research Institute, Indianapolis, IN 46202, USADepartment of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USADepartment of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USAIndiana Biosciences Research Institute, Indianapolis, IN 46202, USAThere are presently no reliable ways to quantify human pancreatic beta cell mass (BCM) in vivo, which prevents an accurate understanding of the progressive beta cell loss in diabetes or following islet transplantation. Furthermore, the lack of beta cell imaging hampers the evaluation of the impact of new drugs aiming to prevent beta cell loss or to restore BCM in diabetes. We presently discuss the potential value of BCM determination as a cornerstone for individualized therapies in diabetes, describe the presently available probes for human BCM evaluation, and discuss our approach for the discovery of novel beta cell biomarkers, based on the determination of specific splice variants present in human beta cells. This has already led to the identification of DPP6 and FXYD2γa as two promising targets for human BCM imaging, and is followed by a discussion of potential safety issues, the role for radiochemistry in the improvement of BCM imaging, and concludes with an overview of the different steps from pre-clinical validation to a first-in-man trial for novel tracers.https://www.mdpi.com/1422-0067/21/19/7274beta cell imagingMRIpancreasPETpre-clinical validationradiochemistry |
| spellingShingle | Stephane Demine Michael L. Schulte Paul R. Territo Decio L. Eizirik Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing International Journal of Molecular Sciences beta cell imaging MRI pancreas PET pre-clinical validation radiochemistry |
| title | Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing |
| title_full | Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing |
| title_fullStr | Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing |
| title_full_unstemmed | Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing |
| title_short | Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing |
| title_sort | beta cell imaging from pre clinical validation to first in man testing |
| topic | beta cell imaging MRI pancreas PET pre-clinical validation radiochemistry |
| url | https://www.mdpi.com/1422-0067/21/19/7274 |
| work_keys_str_mv | AT stephanedemine betacellimagingfrompreclinicalvalidationtofirstinmantesting AT michaellschulte betacellimagingfrompreclinicalvalidationtofirstinmantesting AT paulrterrito betacellimagingfrompreclinicalvalidationtofirstinmantesting AT decioleizirik betacellimagingfrompreclinicalvalidationtofirstinmantesting |